logo
Share SHARE
FONT-SIZE Plus   Neg

FDA Panel Rejects Hemispherx's Ampligen For Chronic Fatigue Syndrome; Stock Down

Hemispherx Biopharma Inc. (HEB) announced the outcome of the meeting of the Arthritis Advisory Committee of the U.S. Food and Drug Administration on the New Drug Application or "NDA" for Ampligen for Chronic Fatigue Syndrome or "CFS".

The vote was 8 to 5 against recommending the approval of Ampligen. However, the Advisory Committee backed safety profile of Ampligen.

Hemispherx said it is committed to the Ampligen clinical development program and to bringing Ampligen to market to ease the suffering of those seriously afflicted with CFS. The company said it will also continue to work closely with the FDA to support the review of this investigational compound. Hemispherx will seek to do everything necessary to confirm in a scientifically rigorous manner that Ampligen is a safe and effective treatment for CFS.

The Prescription Drug User Fee Act ("PDUFA") review goal for the FDA to complete its review of the NDA is February 2, 2013.

HEB is currently trading at $0.28, down $0.08 or 21.39 percent.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Walmart Stores Inc. announced Monday the expansion of its online grocery delivery service to two more markets, Dallas and Orlando. The deliveries will be made through a partnership with Uber. Volkswagen AG's all electric Microbus might be available in market by 2022. As per the plan it would be available first in California. Microsoft Corp. has unveiled a new Minecraft limited edition version of the Xbox One S console during its Gamescom press conference in Germany. The pixelated device comes with 1TB of storage. It includes a custom designed grass block console, Xbox Wireless Controller - Minecraft Creeper, Minecraft system sounds, vertical stand and transparent underside with Redstone circuit accents.
comments powered by Disqus
Follow RTT